https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
https://www.nice.org.uk/news/article/nice-recommends-new-drug-for-people-living-with-obesity
Semaglutide, which goes by the trademark name Wegovy, works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets locations of the brain that manage hunger and food intake. In the largest placebo-controlled trial of the weight-loss medication, individuals who got semaglutide lost 6.2% of their preliminary body weight compared to those who got placebo.
Dr. Garvey has actually functioned as a website principal detective for multi-centered scientific trials funded by Novo Nordisk. Hes likewise gotten monetary compensation from Novo Nordisk for serving on boards of advisers.
This news release is based on abstract 562 at the annual conference of the European Association for the Study of Diabetes (EASD). The product has been peer-reviewed by the congress selection committee. There is no complete paper at this stage.
According to new research study, the innovative new obesity drug semaglutide cuts the risk of type 2 diabetes by more than 50%.
The risk of type 2 diabetes is decreased by more than half by weekly injections of the brand-new obesity drug Wegovy (semaglutide). This is according to brand-new research study being provided at the annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden (September 19-23).
2]
” Semaglutide appears to be the most effective medication to date for treating obesity and is starting to close the space with the amount of weight reduction following bariatric surgery,” states Dr. W. Timothy Garvey, who led the research. He is an endocrinologist and Butterworth Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham, Birmingham, AL, USA.
” Its approval was based on scientific trial results revealing that it minimizes weight by over 15% usually, when used together with a healthy way of life program.
” This quantity of weight reduction is sufficient to deal with or prevent a broad array of obesity complications that hinder health and quality of life and is a game changer in obesity medication.”
Weight problems is understood to increase the risk of type 2 diabetes a minimum of six-fold and Dr. Garvey and coworkers were interested in whether semaglutide might reduce this danger.
To read more, they performed a new analysis of the information from 2 trials of semaglutide.
In STEP1, participants (1,961) with obese or obesity received an injection of 2.4 mg of semaglutide or a placebo weekly, for 68 weeks.
STEP4 involved 803 individuals with obese or weight problems. All got weekly injections of 2.4 mg semaglutide for 20 weeks. They then either remained on semaglutide or were changed to placebo for the next 48 weeks.
Individuals in both trials received advice on diet and workout.
” Given the rising rates of obesity and diabetes, semaglutide might be used efficiently to lower the problem of these chronic diseases.”– Dr. W. Timothy Garvey
The scientists utilized Cardiometabolic Disease Staging (CMDS) to anticipate the individuals risk of developing type 2 diabetes in the next 10 years.
CDMS has been previously revealed to be a highly precise measure of type 2 diabetes danger and is computed utilizing a formula that aspects in a patients sex, age, blood, race, and bmi pressure, along with blood sugar, HDL cholesterol, and triglyceride levels.
In the STEP1 individuals getting semaglutide, 10-year threat ratings for type 2 diabetes reduced by 61% (from 18.2% at week 0 to 7.1% at week 68).
This compares to a 13% decrease in danger score for those offered the placebo (17.8% at week 0 to 15.6% at week 68).
Danger scores mirrored weight reduction, which was 17%, typically, with semaglutide vs 3% with placebo.
At the start of the trial, risk ratings were higher in the participants with pre-diabetes than in those with typical blood sugar levels. However, treatment with semaglutide reduced the risk by a similar quantity in both groups.
In the STEP 4 participants, the biggest decreases in danger scores were seen in the first 20 weeks (from 20.6% at week 0 to 11.4% at week 20). In those who continued receiving semaglutide, the risk score decreased even more to 7.7% however, in those who were switched to placebo, it rose to 15.4%.
This indicates that continual treatment with semaglutide is required to preserve the decrease in type 2 diabetes danger.
Dr. Garvey says: “Semaglutide reduces the future threat of diabetes by over 60% in clients with obesity– this figure is similar whether a patient has prediabetes or typical blood glucose levels.
” Sustained treatment is needed to maintain the advantage.
” Given the increasing rates of weight problems and diabetes, semaglutide could be utilized effectively to decrease the concern of these persistent diseases.”
Notes
2] STEP4 included 803 individuals with overweight or obesity. All received weekly injections of 2.4 mg semaglutide for 20 weeks. They then either remained on semaglutide or were switched to placebo for the next 48 weeks.
This press release is based on abstract 562 at the annual conference of the European Association for the Study of Diabetes (EASD).
